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Abstract
The sleep disorder narcolepsy is associated with symptoms related to either boundary state control that include excessive 
daytime sleepiness and sleep fragmentation, or rapid eye movement (REM) sleep features including cataplexy, sleep 
paralysis, hallucinations, and sleep-onset REM sleep events (SOREMs). Although the loss of Hypocretin/Orexin (Hcrt/
Ox) peptides or their receptors have been associated with the disease, here we propose a circuit perspective of the 
pathophysiological mechanisms of these narcolepsy symptoms that encompasses brain regions, neuronal circuits, cell 
types, and transmitters beyond the Hcrt/Ox system. We further discuss future experimental strategies to investigate brain-
wide mechanisms of narcolepsy that will be essential for a better understanding and treatment of the disease.
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Introduction
The year 2018 marked the 20th anniversary of the simultaneous, 
independent discovery of the hypocretin/orexin peptides by de 
Lecea et al. [1] and Sakurai et al. [2]. The former study described 
the cloning of the “hypothalamus-specific mRNA that encodes 
preprohypocretin, the putative precursor of a pair of peptides 
that share substantial amino acid identities with the gut hor-
mone secretin,” expressed by a restricted number of cells in the 
lateral hypothalamus with widespread projections similar to 
modulatory systems of the brain, and the excitatory nature of 
the hypocretin peptides onto neurons in culture. The later re-
ported “two novel neuropeptides, both derived from the same 
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precursor by proteolytic processing (…) with no significant struc-
tural similarities to known families of regulatory peptides (...) 
that bind and activate two closely related (previously) orphan 
G protein-coupled receptors” that stimulate food consumption 
when injected into the brain of rats.
Soon after the discovery of these novel neuropeptides, it 
was found that loss of Hcrt/Ox signaling results in narcolepsy 
(Figure 1). The cloning of Hcrt-2 receptor mutation in dogs with 
narcolepsy [3], the narcolepsy phenotype of Hcrt/Ox KO mice [2, 
4], the detection of low Hcrt/Ox levels in human narcolepsy [5], 
and the severe loss of Hcrt/Ox neurons in the brains of people 
with narcolepsy [6–8] were critical discoveries. This work laid 
the foundation to establish the Hcrt/Ox system as essential for 
the regulation of arousal and REM sleep and opened up many 
new opportunities for the treatment of people with narcolepsy.
The seventh International Symposium on Narcolepsy 
(September 9–13, 2018) near Boston, MA (USA) gathered scien-
tists and clinicians from all over the world with diverse back-
grounds in genetics, cellular biology, systems neuroscience, 
immunology, psychology, psychiatry, and neurology to review 
progress and define unmet needs. The last two decades have 
substantially improved our understanding of Hcrt/Ox neuro-
transmission, Hcrt/Ox receptor pharmacology, and its clinical 
application, the synaptic connectivity of the Hcrt/Ox neurons, 
their causal control of sleep-to-wake transitions and (hyper-)
arousal during wakefulness, the genetic causes and immune-
mediated pathophysiology of narcolepsy, and the refinement 
of the clinical criteria defining narcolepsy with or without 
cataplexy. Yet, as expected, the meeting emphasized know-
ledge gaps in both the basic mechanisms of Hcrt/Ox neurons in 
normal brain function and in the pathophysiological mechan-
isms underlying narcolepsy.
Reviewing the current state of knowledge led us to questions 
such as, What are the mechanisms underlying cataplexy, sleepi-
ness and other symptoms of narcolepsy? How do these symptoms 
result from alterations of circuit-specific neuromodulation (nor-
epinephrine, histamine, dopamine, acetylcholine, neuropeptides)? 
How does circadian cycling influence brain activity and behavioral 
manifestation of cataplexy?
Below, we summarize our opinions and those of other re-
searchers. While loss of Hcrt/Ox signaling is the primary cause of 
narcolepsy, we believe that the symptoms arise from a broader 
network centered on hypothalamic input–output connections. 
We also summarize the connectivity and dynamics of Hcrt/Ox 
cellular networks across sleep–wake states, and also locomo-
tion, food intake and reward, and eventually integrate the novel 
concepts driving experimental research on the mechanisms of 
cataplexy.
Lost in Transitions: Current Models of 
Cataplexy
Cataplexy is the most extraordinary symptom of narcolepsy 
type 1 (narcolepsy with cataplexy). Cataplexy is characterized 
by episodes of muscle weakness triggered by strong and gener-
ally positive emotions. In people with narcolepsy, cataplexy is 
often partial, resulting in face and neck weakness. Full episodes 
of cataplexy, in contrast, can produce severe global weakness in 
which an individual slumps to the ground, unable to move or 
speak for seconds to a minute or two, but consciousness is fully 
preserved. Additional abnormalities include frequent waking 
from sleep, inability to maintain wakefulness during the active 
(wake) phase accompanied with sleep attacks, and intrusions of 
REM sleep-like events, that is, cataplexy intruding into wakeful-
ness, or the premature appearance of REM sleep soon after sleep 
onset, that is, sleep onset REM (SOREM) events (Figure 2).
The symptoms of narcolepsy, including cataplexy, have been 
interpreted as resulting from an instability of sleep–wake states 
often loosely referred to as “poor state boundary control” [9]. An 
area of current controversy regarding state instability pertains to 
its understanding, or definition, particularly as it relates to cata-
plexy. For example, cataplexy may be interpreted as resulting 
from the intrusion of REM sleep muscle atonia into wakefulness. 
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Figure 1: Pathophysiology of narcolepsy. (A–D) Hypocretin and MCH mRNA expression in the hypothalamus of a control subject and a person with narcolepsy. 
Preprohypocretin transcripts are detected in the hypothalamus of a control (B) but not in a narcolepsy (A) subject, while MCH transcripts are detected, intermingled 
with hypocretin in both control (D) and narcolepsy (C) samples. f, fornix scale bars = 10 mm. Adapted from Peyron et al. (2000). (E) Strong, positive emotions many ac-
tivate neurons in the medial prefrontal cortex (mPFC) that excite neurons making orexin and MCH as well as neurons in the amygdala. Normally, the orexin neurons 
would then excite atonia-suppressing neurons of the ventrolateral periaqueductal gray/lateral pontine tegmentum (vlPAG/LPT), but in the absence of orexins, the in-
hibitory effects of MCH and the amygdala are unopposed. Lacking inhibition from the vlPAG/LPT, the sublaterodorsal nucleus (SLD) can then inhibit motor neurons via 
GABA and glycine-containing neurons of the medial medulla. Norepinephrine from the locus coeruleus (LC) normally inhibits REM sleep and cataplexy, and the LC is 
probably inhibited during cataplexy, perhaps via the amygdala and MCH neurons. This model is built upon research derived from many labs, but its basic components 
are still debated and remain to be definitively demonstrated. Pathways active during cataplexy are shown with solid lines; pathways inactive during cataplexy are 
shown with dashed lines. Inhibitory pathways are purple; excitatory pathways are green.
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This perspective would suggest that cataplexy is triggered when 
executive neural circuits driving REM sleep inappropriately activate 
during wakefulness, thus producing a “dissociated state” containing 
elements of both REM sleep and wakefulness. Alternatively, the 
underlying mechanisms of muscle atonia during cataplexy may 
be different from those of REM sleep, suggesting instead, that 
cataplexy is an entirely distinct state potentially unrelated to either 
REM sleep or wakefulness. Currently, these two models, or inter-
pretations, of cataplexy are based on complementary sets of ex-
perimental evidence and interpretations (Figure 2).
On the one hand, researchers have speculated since the 1980s 
that cataplexy, hypnagogic hallucinations, and sleep paralysis 
are simply elements of REM sleep that mix into wakefulness, 
creating dissociated states [9, 10]. This longstanding hypothesis 
suggests that during an episode of cataplexy, some of the neural 
pathways involved in muscle atonia during REM sleep are transi-
ently activated by, for example, strong positive emotions during 
wakefulness. Further support for this hypothesis is the obser-
vation that transitions between states of vigilance are more fre-
quent in human narcolepsy and animal models of narcolepsy 
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Figure 2: Circuit perspective of narcolepsy. Schematic representation of the physiological elements underlying the symptoms of narcolepsy, including excessive daytime 
sleepiness, sleep fragmentation, cataplexy, hypnagogic hallucinations, SOREMS and sleep paralysis. These are divided into symptoms related to boundary state control (high-
lighted in the green box) or REM sleep (highlighted in the blue box) and are distributed across the sleep–wake cycles (top part of the figure). The bottom part of the figure 
highlights possible mechanisms involving neural circuits of boundary state control (top) and REM sleep (bottom). In this schematic representation, primary circuit hubs 
controlling sleep wake state (top) or REM-related brain activity or phenomena (bottom) are represented by large dots connected to each other; smaller dots represent 
secondary output circuits. Color coding indicates active (red) or inactive (green) networks and pathways. Some of the symptoms of narcolepsy are thought to result 
from a weak boundary state control. For example, in the absence of excitatory Hcrt/Ox drive, excessive daytime sleepiness could arise from weak or inconsistent activity of 
wake-promoting systems, or inappropriate intrusion of NREM sleep-promoting regions. Similarly, sleep fragmentation could result from uncoordinated activity of wake-
promoting neurons during sleep. Abnormal activity in REM sleep circuits may produce other symptoms of narcolepsy including cataplexy during wakefulness, hypna-
gogic hallucination during NREM sleep, and SOREMS or sleep paralysis during REM sleep. In the context of this perspective, cataplexy may result from overactivity of REM 
sleep circuits during wakefulness (hyperactivity model) or hypoactivity of REM-suppressing circuits (hypoactivity model) and the activation of brain circuits governing 
theta rhythm or muscle atonia. Hypnagogic hallucinations occur at the transition from wakefulness to sleep and may result from the activation of REM sleep circuits that 
promote dreaming/imagery and sometimes muscle atonia (paralysis). SOREMs implicate a comprehensive activation of REM sleep circuits, including those responsible 
for theta rhythms, muscle atonia, eye movements, dreaming/imagery and the autonomic system. Finally, hypnopompic hallucinations and sleep paralysis may result from 
the co-activation of both wake and REM circuits, in particular those involved in muscle atonia, dreaming/imagery and the autonomic system.
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[11] and that REM sleep, as well as cataplexy, seems to be under 
the inhibitory control of the Hcrt/Ox neuropeptides [12], despite 
a normal pattern of cortical EEG signals across wake, NREM and 
REM sleep transitions. In one popular model, REM sleep-active, 
glutamatergic neurons of the sublaterodorsal nucleus activate 
GABA/glycinergic pre-motor neurons which then strongly in-
hibit alpha-motor neurons to produce muscle atonia [13, 14]. 
Lacking contrary evidence, most researchers have assumed 
that cataplexy is mediated by the abnormal activation of these 
REM sleep atonia pathways during wakefulness. However, this 
common assumption remains to be confirmed experimentally.
In contrast, more recent data have suggested that cataplexy 
and REM sleep involve distinct states of brain activity and be-
havior [15]. This perspective is based on the finding that while 
EEG activity during cataplexy is similar to that of REM sleep, it also 
has some distinct features such as bursts of hypersynchronous 
theta activity [15]. Furthermore, this hypothesis is supported by 
the finding that, in contrast to REM sleep, the onset, mainten-
ance, and termination of cataplexy is a multi-phased process 
involving a progression of behavioral states beginning with 
wakefulness. This hypothesis would be further supported if the 
muscle atonia mechanisms of cataplexy were found to be dif-
ferent than the control of muscle atonia observed in REM sleep. 
Thus, understanding boundary state control in narcolepsy will 
likely be the subject of future investigation.
Finally, there is a common manifestation of cataplexy across 
species, from rodents to humans, that is, cataplexy often transi-
tions into a state indistinguishable from REM sleep. The differ-
ence between sleep-onset REM sleep (SOREM) and cataplexy is 
clearly defined in human narcolepsy, however, it remains diffi-
cult to differentiate in mice, particularly since intervening NREM 
sleep may be very brief. Some studies have tracked the absence of 
a masseter muscular tone to confirm cataplexy in mice [16], while 
others have distinguished “abrupt” versus “gradual” arrests when 
comparing cataplexy in Hcrt/Ox KO and OX2 receptor−/− mice [17], 
as it might differentiate SOREM versus cataplexy. These findings 
are indicative of a possible link between the behavioral states pre-
ceding cataplexy and the forthcoming cataplexy [17] that should 
be considered in future investigation in human.
Hcrt/MCH Duality in Cataplexy
Current models of narcolepsy mainly focus on the loss of Hcrt/
Ox neuron signaling. However, other neurotransmitters and cir-
cuits likely contribute to the pathophysiology of the disease. 
Indeed, there is no clear understanding of how the loss of Hcrt/
Ox signaling leads to the production of cataplexy. Elucidating 
these circuits is an area of strong interest that may open av-
enues of future clinical intervention for people with cataplexy.
One of the emerging themes in the field is the potential 
interplay between the MCH and Hcrt/Ox neuronal systems in 
the control of both REM sleep and cataplexy. These two neur-
onal populations are intermingled within the LH, a critical brain 
region that integrates diverse inputs related to energy balance, 
sleep pressure and circadian time for the output modulation 
of behavioral state and global shifts in resource allocations 
required for sleep or wakefulness [18–20]. MCH and Hcrt/Ox 
neurons show reciprocal, state-dependent, firing patterns with 
the former being maximally active during REM sleep and the 
latter predominantly active during wakefulness. In addition, 
GABA receptors on MCH and Hcrt/Ox neurons undergo dynamic 
and differential changes during the sleep–wake cycle [21]. GABA 
receptors on Hcrt/Ox neurons appear to increase during waking 
and sleep deprivation, during which Hcrt/Ox activation is as-
sumed to be prolonged, but decrease during sleep when Hcrt/Ox 
neurons are typically silent. Neighboring MCH neurons, in con-
trast, show the opposite pattern of GABA receptor expression, 
increasing during sleep when MCH neurons are most active 
and decreasing during wake when these neurons are typically 
silent. It was proposed that this reciprocal expression of GABA 
receptors on MCH and Hcrt/Ox neurons may play a role in the 
homeostatic adjustment of their respective activity patterns 
as a function of preceding sleep and wake duration [19]. The 
role of this differential expression in homeostatic sleep–wake 
regulation, and also cataplexy or REM sleep-like brain activity, 
are potential implications of this work that requires further 
investigation.
Another hypothesis is that a loss of Hcrt/Ox signaling may 
favor MCH neuron activation, potentially driving the increased 
REM sleep propensity found in narcolepsy. This hypothesis 
is largely based on the reciprocal firing patterns of these two 
neuronal populations suggesting a reciprocal inhibition [22, 23], 
given that MCH activity is maximal in REM sleep whereas Hcrt/
Ox activity is maximal in wake. Although a growing body of lit-
erature demonstrates that the MCH system plays an important 
role in REM sleep expression, a role for MCH in narcolepsy or 
cataplexy has remained unknown. Using a global measure of 
MCH level of release in the CSF, no difference was seen between 
people with narcolepsy, central hypersomnias or controls [24]. 
However, recently published data show that MCH neuronal ac-
tivation in Hcrt-KO mice leads to an increase in both REM sleep 
and cataplexy, whereas administration of an MCH receptor an-
tagonist decreases cataplexy [25]. These data would suggest that 
the MCH system can drive both REM sleep propensity and in-
trusions of its associated muscle atonia (cataplexy) into wake-
fulness. However, these data contrast with previous studies 
showing an increase of cataplexy in [Hcrt/Ox -MCH] double, as 
compared to Hcrt/Ox single, knockout mice [26].
Reconciling these opposing views regarding the role of MCH 
in cataplexy may potentially provide insight into mechanisms 
causing boundary state instability in narcolepsy. To illustrate, 
one can ask is cataplexy caused by overactivation of neural circuits 
responsible for muscle atonia, or brain activity typical of REM sleep? 
The answer to this fundamental question has significant im-
plications. For example, if both REM sleep and cataplexy are 
triggered by similar mechanisms, then experimental condi-
tions increasing REM sleep propensity would be expected to 
increase cataplexy by causing REM sleep-related phenomena 
such as muscle atonia to intrude into wakefulness as recently 
reported [27]. Another perspective is that acute changes in 
MCH signaling [27] may differ from chronic loss of MCH [28] on 
sleep boundaries. Alternatively, if cataplexy occurs when both 
Hcrt/Ox (waking) and MCH (REM sleep) systems are simultan-
eously hypoactive, then boundary state instability may ensue 
when neither the Hcrt/Ox nor MCH system predominates. If 
correct, then experimental conditions should thus be capable 
of dissociating these phenomena, that is, increasing cataplexy 
while decreasing REM sleep, or at least brain activity similar to 
REM sleep. In this latter perspective, activation of systems that 
drive REM sleep would shift network activity toward this sleep 
state and decrease the probability for cataplexy by stabilizing 
REM sleep and the boundary between REM sleep and wake.
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More work is clearly needed to clarify the role of the MCH 
and Hcrt/Ox systems in both cataplexy and the increased REM 
sleep propensity of narcolepsy. With respect to the “mutual 
inhibition” models of sleep–wake states [29], it is conceiv-
able that a number of circuit inputs to Hcrt/Ox cells, and pos-
sibly their post-synaptic targets, may ultimately contribute 
to sleep–wake instability or even cataplexy. Lack of Hcrt/Ox 
may induce pre- and post-synaptic changes that make muscle 
atonia circuits more responsive to atonia-promoting inputs 
other than those of Hcrt/Ox origin. Although this latter hy-
pothesis is often discussed, it implies that the underlying 
circuits of REM sleep atonia are essentially “highjacked” in 
waking during cataplexy, an assumption that has yet to be ex-
perimentally demonstrated.
Hcrt/Ox Neuron Connectivity and 
Hypothalamic Control of Behaviors
An open question remains as to whether Hcrt/Ox neurons form 
a homogenous cell population within the lateral hypothalamus, 
or whether there are distinct Hcrt/Ox cell clusters that exhibit 
different afferent/efferent projection maps, and therefore dif-
ferent activity patterns, physiological or behavioral phenotypes, 
which may ultimately deepen our understanding of the etiology 
and phenotype of narcolepsy.
Previous studies have examined Hcrt/Ox neuronal afferent 
and efferent projections using classically and genetically tar-
geted neuroanatomical tracing methods in rodents. These 
studies reveal that Hcrt/Ox neurons integrate a wide variety 
of neural signals from multiple sources distributed all over 
the brain [30–32]. Quantitative estimates of the relative projec-
tion densities show dense monosynaptic inputs from the lat-
eral and paraventricular hypothalamus, cerebral nuclei such as 
the nucleus accumbens and bed nuclei of the stria terminalis 
(BNST), as well as from the lateral habenula, midbrain reticular 
nucleus, and periaqueductal gray; some inputs from the cortex 
and brainstem have also been reported [30]. Accordingly, Hcrt/
Ox neurons are excited by a wide variety of neurotransmitters 
including glutamate [33], ATP [34], corticotropin releasing factor 
[35], thyrotropin releasing hormone [36], noradrenaline [37], and 
acetylcholine [33, 37], and inhibited by GABA [33] and adenosine 
[38, 39].
Recent studies have defined neurochemical inputs from spe-
cific sources, such as GABAergic [40], corticotropin releasing 
factor, and cholecystokin-projecting neurons from the BNST 
[41], to be essential for arousal modulation. Interestingly, local 
GABAergic control of Hcrt/Ox is depressed by cholinergic or 
noradrenergic input to the LH39. Moreover, although the inhibi-
tory GABAergic interneurons are not affected by Hcrt, they ap-
pear inhibited by dynorphin which is co-released from Hcrt/Ox 
collaterals [40]. These and other data demonstrate how Hcrt/
Ox neurons may be disinhibited by other waking systems (i.e. 
acetylcholine) or by their own release of dynorphin.
In turn, Hcrt/Ox neurons project diffusely throughout the 
brain, with especially dense excitatory projections to brain areas 
regulating arousal (e.g. locus coeruleus and tuberomamillary 
nucleus), reward (e.g. ventral tegmental area and nucleus 
accumbens) and autonomic function (e.g. brainstem sympa-
thetic and respiratory control centers). Postsynaptic excita-
tory responses to optogenetic activation of Hcrt/Ox terminals 
demonstrate the involvement of both Hcrt/Ox peptides and 
glutamate neuro-transmission/modulation of the activity of 
post-synaptic targets, for example histamine or noradrenergic 
neurons [42, 43].
Electrical activity in Hcrt/Ox neurons correlates with states 
of heightened arousal, and, electrophysiological and calcium 
transient recordings from identified Hcrt/Ox neurons in vivo 
broadly suggest that these neurons are more active during states 
of wakefulness and silent during NREM sleep (but with some re-
sidual phasic activity during REM sleep). Importantly, Hcrt/Ox 
neurons also increase activity during the presence of salient en-
vironmental stimuli (e.g. predator odor, somatosensory stimula-
tion, immobilization stress) and active behaviors (e.g. running) 
while decreasing activity during quiet, sedentary behaviors (e.g. 
eating, grooming) [44, 45]. Although the mechanisms by which 
these context-specific activity dynamics arise from specific 
neural inputs is an open question, recent and future studies 
examining the effects of stimulating specific afferent projec-
tions to Hcrt/Ox neurons will help dissect the contributions of 
input from distinct brain regions [41].
Some recent studies have proposed that Hcrt/Ox neurons can 
be anatomically and functionally clustered into at least two sep-
arate subpopulations: one that resides in the medial Hcrt/Ox field 
sends projections to the locus coeruleus and tuberomammillary 
nucleus to regulate wakefulness; and another that resides in the 
lateral Hcrt/Ox field and sends projections to the ventral teg-
mental area and nucleus accumbens to regulate reward [46]. 
Although further studies have found some evidence to support 
this hypothesis [47, 48], others have observed projections to 
locus coeruleus and the ventral tegmental area to be in equal 
frequencies across the Hcrt/Ox field [49, 50]. Most recently, Iyer 
et al. identified distinct Hcrt/Ox neuron subtypes that projected 
to both the locus coeruleus and tuberomammillary nucleus, or 
to the ventral tegmental area and nucleus accumbens, but these 
two categories of Hcrt/Ox neurons were intermingled among 
the Hcrt/Ox field [51]. At the cellular level, Hcrt/Ox neurons can 
be functionally subdivided into two populations based on their 
electrophysiological properties, but whether these categories of 
neurons participate in distinct behaviors will require future in-
vestigation [52]. Interestingly, a recent molecular study suggests 
a weak molecular heterogeneity amongst Hcrt/Ox neurons, 
indicating that circuit-specific Hcrt/Ox cell functions is rather 
due to connectivity (inputs–outputs) than molecular content 
[53]. This is in agreement with the fact that Hcrt/Ox neurons are 
all born at E12 [54] in contrast to MCH neurons that have clear 
2 subpopulations (CART+ and CART−) but both seem to be in-
volved in REM sleep [55].
Efforts to identify transcriptome profiles in more detail (e.g. 
RNA-seq or Drop-seq) of a genetically defined Hcrt/Ox neuronal 
population in animal models [56], together with a refined identi-
fication of functional clusters of Hcrt/Ox neurons based on their 
discharge patterns across sleep–wake states and goal-directed 
behavior will be essential in refining our understanding of the 
multiple aspects of Hcrt/Ox control of brain states, in particular 
during cataplexy and goal-directed behaviors.
Activity of Brain Circuits in the Absence of a 
Hcrt/Ox System
Although the link between Hcrt/Ox cells and spinal motor 
neurons remains poorly defined [57], an important challenge re-
mains to determine how the absence of Hcrt/Ox neurons leads 
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to cataplexy and REM sleep-like brain activity at the circuit level. 
An equally important question is whether cataplexy results 
from a sudden or, instead, a progressive (long-term) cellular or 
circuit change requiring secondary or compensatory mechan-
isms. These changes of cellular and circuit activity in animal 
models of narcolepsy are summarized below (Figure 2).
A growing body of clinical and experimental evidence suggests 
a circuit mechanism for cataplexy that encompasses a larger net-
work than just Hcrt/Ox neurons and their direct targets. Indeed, 
spiking activity of multiple neuronal populations exhibit altered 
activity during cataplexy in animal models of narcolepsy. On one 
hand, cataplexy is associated with an increased neuronal spiking 
in a subpopulation of non-cholinergic REM-ON neurons from the 
medial medulla (their activity during cataplexy is higher than 
during wake and similar to REM sleep) [58], dorsal raphe REM-OFF 
(presumably serotoninergic) and unidentified REM-ON neurons 
(their activity during cataplexy is similar to their activity during 
NREM sleep) [59], histaminergic wake-ON cells (their activity 
during cataplexy is similar to their activity during wake) [60]. In 
contrast, medial mesopontine neurons (their activity during cata-
plexy is similar to their activity during quiet wake) [61] and un-
identified neurons from the locus-coeruleus (their activity during 
cataplexy is similar to their activity during REM sleep) [62] showed 
reduced activity at the onset of, and during, cataplexy relative to 
their activity during either REM sleep or active waking, respect-
ively. Interestingly, transient silencing of LC noradrenergic cells is 
insufficient to induce cataplexy, although their sustained activa-
tion which may then be followed by depolarization block which in-
duces behavioral arrests that resemble cataplexy [63]. Collectively, 
these findings suggest that cataplexy results from the activation 
of REM sleep atonia circuits during wakefulness, some of which 
may include the SLD neurons responsible for REM sleep atonia [64], 
and the cessation of activity of wake-promoting neurons such as 
the norepinephrine cells. A complete representation of brain ac-
tivity during cataplexy will be essential to the understanding of the 
pathophysiology of narcolepsy.
At the cellular level, the lack of a functional Hcrt/Ox system 
in the brains of people with narcolepsy profoundly alters  sev-
eral neuromodulatory systems. In particular, hyper-sensitivity 
to cholinergic stimulation [65], a dependence on opiod [66] and 
histaminergic [60, 67] systems have been reported. Whether these 
translate into altered neuromodulatory tone, through alteration of 
their release, receptor expression or membrane trafficking remains 
unknown. Furthermore, drugs that enhance cataplexy reduced 
spontaneous LC activity during the time that the propensity for 
cataplexy was enhanced [62], suggesting that LC norepinephrine 
neurons, and disfacilitation of motoneurons, may be permissive to 
the onset of cataplexy. Accordingly, both prazosin and physostig-
mine greatly increased the propensity for cataplexy. Thus, these 
findings further support the implication of multiple neural circuits, 
and a possible role for compensatory mechanisms underlying the 
development of some symptoms of narcolepsy.
A remarkable observation is the association between positive 
emotions and the triggering of cataplexy in people with narcolepsy 
(laughing, joking, social interaction with friends and family), which 
has focused experimental investigation on the role of amygdala 
circuits in cataplexy. The amygdala is essential to the processing 
of emotional stimuli and has dense projections to brainstem re-
gions regulating muscle tone and sleep. Two populations of cells 
within the amygdala show a significant change in spiking activity 
with respect to cataplexy [68]; a first sub-population of sleep-active 
neurons located in the central and basal nuclei increase discharges 
prior to, and during, cataplexy, while a second sub-population of 
wake-active cells from the cortical nucleus exhibits the inverse re-
sponse. Lesions of the amygdala in mice with narcolepsy decrease 
cataplexy triggered spontaneously, or with high arousal or posi-
tive emotions, without altering their sleep–wake cycle [10]. In 2017, 
GABAergic neurons of the amygdala were found to be necessary 
for cataplexy [69] (but see Ref. [16]), suggesting that these inhibitory 
cells may be implicated in cataplexy induced by positive emotions. 
Whether other cell types in the amygdala, or extra-amygdala cir-
cuits, are involved in the initiation, maintenance and termination 
of cataplexy attacks remains to be investigated. Of interest, revers-
ible suppression of medial prefrontal cortex activity substantially 
reduced cataplexy induced by chocolate, but did not affect spontan-
eous cataplexy [70]. In addition, neurons in the medial prefrontal 
cortex innervate parts of the amygdala and hypothalamus that 
contain neurons active during cataplexy and that innervate brain-
stem and spinal motor systems. In this context, the implication 
of dopamine [71], together with the oxytocinergic system in emo-
tion and social interactions, in triggering cataplexy remains to be 
investigated.
At the level of circuit oscillation, electroencephalographic (EEG) 
features of cataplexy were recorded from people and mice with 
narcolepsy [15, 72, 73] where cataplexy was divided into three 
distinct stages. The initial “wake-like” stage involved tonic sup-
pression of EMG activity, full postural collapse and a waking-like 
EEG spectrum. A second “REM-like” stage differed from the pre-
vious one by the onset of hypersynchronous hippocampal theta 
activity and a REM-like EEG spectrum (large amplitude EEG sig-
nals and high peak theta frequency). The final transitional stage to 
wakefulness or NREM sleep is accompanied with EEG activities of 
mixed amplitude and frequencies (but see Ref. [15]). Finally, long 
periods of cataplexy may evolve into REM sleep [15]. Altogether, 
these data somewhat contradict the hypothesis that cataplexy 
shares identical EEG and behavioral characteristics with REM 
sleep. Despite their differences, murine cataplexy shares many 
EEG features with REM sleep, or the pre-REM sleep spindling [4, 
26]. Once cataplexy is fully established, the mouse cortical EEG is 
dominated by REM-like high amplitude theta activity with tran-
sient prefrontal theta bursts not of hippocampal origin [15] and 
also seen in histamine deficient mice [74]. Consistent with this 
observation, wakefulness preceding cataplexy displays rich theta 
and gamma rhythms possibly due to higher locomotor activity 
and low delta wave activity. Of importance, theta activity is higher 
during cataplexy than wakefulness in mice [75].
Currently, this research provides an incomplete map of 
single cell and circuit activity in narcolepsy. One way to provide 
missing information would be to simultaneously track the ac-
tivity of multiple brain circuits, including those implicated in 
the control of sleep–wake states, muscle tone, and emotion (e.g. 
dopamine, serotonin) at single-cell resolution in healthy and 
people with conditions.
Future directions
Cataplexy results from complex, yet unclear, pathophysiological 
mechanisms that involve neural circuits distributed throughout 
the brain, in particular in the amygdala, prefrontal cortex and 
brainstem. Whether cataplexy is a simple intrusion of REM sleep, or 
some aspect of it, into wakefulness, or rather represents a unique 
state that is distinct from REM sleep remains to be determined.
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Furthermore, questions remain such as, From where does this 
pathological circuit activity arise? and How can one accurately 
restore a naturalistic activity in these circuits? The activation of 
cataplexy-silent neurons (e.g. locus coeruleus norepinephrine 
neurons), or silencing of cataplexy-active neurons may be sufficient 
to block some of the narcolepsy symptoms including cataplexy, 
yet this remains to be investigated. Addressing these questions 
requires a much more precise understanding of the cellular and 
circuit dynamics of a “narcoleptic brain” than what is available 
thus far. Equally important is the need to harmonize methodo-
logical approaches across research labs. For example, scoring of 
sleep–wake states in rodents in a recent study [25] was based on 
12-s epochs, whereas many labs score sleep–wake data based on 
4-s epochs. Thus, longer epochs are more likely to contain tran-
sitional states such as NREM sleep. This is important since REM 
sleep and cataplexy demonstrate very similar polysomnographic 
features, and their differentiation relies heavily on the presence or 
absence of intervening NREM sleep, as well as distinct cellular ac-
tivity amongst circuits described in this perspective.
In this context, brain-wide simultaneous recording/imaging 
of multiple circuits across states of higher arousal (e.g. during 
goal-directed behaviors), sleep or cataplexy in animal models 
of narcolepsy is expected to shed light on the pathophysio-
logical mechanisms. Long-term perspectives aim at better 
understanding the molecular, cellular and circuit substrates of 
narcolepsy symptoms through a particular attention to the lon-
gitudinal aspect of the disease and the brain compensatory re-
sponse to the absence of a functional Hcrt/Ox system.
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